Hims & Hers stock closes at one-year low amid battle over compounded Wegovy pill
Original Report
Hims & Hers also said it’s selling a cancer-detection test that’s featured in its Super Bowl ad, which plays like a commentary on the wealthy’s access to better healthcare.
Glass House Analysis
This story reflects the interconnected nature of modern economic systems, where developments in one sector inevitably affect others. Understanding these connections is essential for grasping how policy decisions and market movements translate into real-world outcomes for families, workers, and communities. The economy is not an abstract system of numbers—it's the sum total of decisions about who works, who prospers, and who struggles.
The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.
Enjoyed this analysis?
Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.
No spam. Unsubscribe anytime.
More Stories
The economics of the NBA trading deadline (from my email)
From an anonymous correspondent: Perhaps, as NBA fan, there’s a column to be written about the incentives that drove the NBA trade market: namely the all-out search to avoid/get out of the luxury tax...
Dow surges 1,200 points for first close above 50,000 in sharp rebound from tech rout: Live updates
Friday's rebound followed several days of heavy selling in the tech sector.
Tech AI spending may approach $700 billion this year, but the blow to cash raises red flags
Tech's megacaps announced major increases in capex spend for 2026, and now investors are preparing for cash to dwindle.
FDA to restrict GLP-1 ingredients used in non‑approved compounded drugs
The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.